NVIDIA and Eli Lilly announced a $1 billion collaboration to build an AI-powered drug discovery laboratory in the San Francisco Bay Area. The partnership will combine NVIDIA’s AI hardware and software with Lilly’s drug development expertise to accelerate target identification, molecule design, and preclinical candidate selection. The lab will deploy large-scale models and high-performance computing to shorten discovery cycles and enable higher-throughput translational work. Lilly and NVIDIA said the effort will focus on workflows that integrate generative AI, simulation and biological datasets to surface drug candidates faster. The move underscores Big Tech’s deeper industrial ties to pharma R&D and the continued prioritization of AI as a productivity lever for pipeline generation.